Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Deals PIC

CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy

Fineline Cube Sep 10, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug

Sandoz Receives Positive CHMP Review for Trastuzumab Biosimilar in HER2-Positive Cancers

Fineline Cube Sep 19, 2023

Sandoz (SWX: SDZ), the generic and biosimilar drug maker set to separate from Novartis (NYSE:...

Policy / Regulatory

NMPA Drafts Quality Management Norms for Online Medical Device Sales

Fineline Cube Sep 19, 2023

The National Medical Products Administration (NMPA) has issued the “Medical Device Online Sales Quality Management...

Policy / Regulatory

NMPA Seeks Comments on Medical Device Classification Draft Proposal

Fineline Cube Sep 19, 2023

The National Medical Products Administration (NMPA) has issued a notification focusing on the definition and...

Company Drug

Gilead’s Kite CAR-T Therapy Yescarta Achieves 71% CMR in Phase II Trial for R/R LBCL Patients

Fineline Cube Sep 19, 2023

Gilead’s (NASDAQ: GILD) subsidiary Kite has announced early results from a Phase II trial of...

Company Deals

Pharmanovia Bolsters Neurology Portfolio with Acquisition of Sanofi’s CNS Products

Fineline Cube Sep 19, 2023

UK-based healthcare company Pharmanovia has announced the expansion of its neurology portfolio through the strategic...

Company Deals

Tonghua Dongbao Pharmaceuticals Partners with King-Friend Biochemical on Insulin Development

Fineline Cube Sep 18, 2023

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has entered into a partnership with fellow Chinese firm...

Company Drug

EMA’s CHMP Backs Enhertu for Advanced NSCLC with HER2 Mutations

Fineline Cube Sep 18, 2023

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Deals

BMS Expands Partnership with Samsung Biologics for Oncology Drug Manufacturing

Fineline Cube Sep 18, 2023

Global pharmaceutical company Bristol-Myers Squibb (BMS; NYSE: BMY) has announced an expansion of its existing...

Company Drug

EMA’s CHMP Recommends Approval of Keytruda as Adjuvant NSCLC Treatment

Fineline Cube Sep 18, 2023

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Drug

Novartis’s Kisqali Reduces Cancer Recurrence Risk in HR+/HER2- Early Breast Cancer: Phase III Results

Fineline Cube Sep 18, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has published results from a Phase III study of...

Company

CanSino Biologics Reports H1 2023 Revenues Down 96.7% YOY, COVID-19 Demand Decreases

Fineline Cube Sep 18, 2023

China-based CanSino Biologics (SHA: 688185, HKG: 6185) has released its financial report for the first...

Company Deals R&D

GemPharmatech Partners with Daxiang Biotech to Advance Preclinical Evaluation Models

Fineline Cube Sep 18, 2023

Nanjing-based GemPharmatech Co., Ltd, a center for laboratory animal seed resources and a specialist in...

Company Drug

Akeso Biopharma’s AK132 Receives Green Light for Clinical Trial in Advanced Solid Tumors

Fineline Cube Sep 18, 2023

Akeso Biopharma’s (HKG: 9926) AK132, a bispecific antibody (BsAb) targeting Claudin18.2 and CD47, has received...

Company Medical Device

AcornMed Receives FDA Breakthrough Device Designation for Urothelial Carcinoma Liquid Biopsy

Fineline Cube Sep 18, 2023

Beijing-based tumor precision medicine specialist, AcornMed, has been granted Breakthrough Device Designation (BDD) by the...

Company Deals Digital

Baidu Health Partners with HOB Biotech to Innovate Allergy Detection and Treatment

Fineline Cube Sep 18, 2023

Baidu Health has entered into a strategic partnership with HOB Biotech Group, a leading in...

Company Medical Device

Tuodao Medical’s Percutaneous Puncture Surgery Robot NP100 Approved in China

Fineline Cube Sep 18, 2023

China-based surgical robot developer Tuodao Medical Technology Co., Ltd has received marketing approval for its...

Company Drug

CSPC Pharmaceutical Group Receives NMPA Approval for Irinotecan Liposome Injection

Fineline Cube Sep 18, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received market approval...

Company Medical Device

Jenscare Scientific’s Tricuspid Valve Replacement System Joins FDA’s TAP Program

Fineline Cube Sep 18, 2023

Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced that...

Legal / IP

Jiangsu Hengrui Pharmaceuticals Entangled in Legal Disputes with BeyondSpring and Reistone

Fineline Cube Sep 18, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) is currently entangled in legal challenges involving...

Company

Astellas Pharma Invests EUR 330 Million in State-of-the-Art Manufacturing Plant in Ireland

Fineline Cube Sep 15, 2023

Japanese pharmaceutical company Astellas Pharma (TYO: 4503) has announced a significant investment of EUR 330...

Posts pagination

1 … 524 525 526 … 718

Recent updates

  • Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers
  • METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform
  • Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection
  • CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours
  • HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Company Drug

CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.